Skip to content

Trial · Interventional

CompletedNot applicableResults postedRegistry data

Cervical Ripening in Premature Rupture of Membranes

Overview

Status
Completed
Phase
Not applicable
Enrollment
230 participants (actual)
Sponsor
Montefiore Medical Center · Other
Design
Randomized · Open label (no masking)
Countries
1 country

United States

Start
1 Oct 2014
Primary completion
30 May 2016
Completion
30 May 2016
First posted
11 Dec 2014 (estimated)
Last update posted
10 Aug 2021
Conditions
Pregnancy · Premature Rupture of Membranes · Preterm Premature Rupture of Membranes · Unfavorable Cervix

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2014201520162017
  1. N/A

    Cervical Ripening in Premature Rupture of Membranes

    NCT02314728

    1 Oct 2014 to 30 May 2016

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Premature rupture of membranes (PROM) is diagnosed by demonstrating amniotic fluid in the vaginal canal before the onset of labor. The integrity of the amniotic membrane is compromised thereby increasing the risk of intrauterine infection and compression of the umbilical cord. PROM complicates 3% to 8% of pregnancies in the US and is responsible for 30% of preterm births. Intrauterine infection remains the most significant maternal and neonatal sequelae associated with PROM and this risk increases with the length of time from ruptured membrane to delivery. Induction of labor has been shown to reduce the rates of chorioamnionitis, endometritis and NICU admissions4. Specifically, induction of labor with prostaglandin agents followed by oxytocin, versus oxytocin alone has been shown to be effective for labor induction resulting in vaginal delivery. Management strategies for PROM have been controversial, and published studies on outcomes are over one to two decades old, which does not account for changes in clinical trends and practice patterns. Recently ACOG recommends that patients presenting at 37 weeks gestation or greater with PROM should be induced if not in labor, and "generally with oxytocin". In women with PROM without the onset of labor, the cervix is commonly unfavorable and induction with oxytocin alone may lead to an increased risk of cesarean section. With a c-section rate as high as 33%, women undergoing induction of labor have an increased risk of c-section and its associated morbidity and long term sequela. ACOG's recommendation for the use of oxytocin as the induction agent may be meant to avoid a theoretical increased risk of chorioamnionitis in this patient population however it does not take into account the status of the cervix, which may result in a increased risk of c-section. The purpose of the proposed study is to determine whether cervical ripening in women with PROM and an unfavorable cervix is associated with increase rates of vaginal delivery and decreased cesarean section rate compared to induction of labor with oxytocin alone. The investigators aim to determine the incidence of endometritis, and neonatal infection associated with PROM in the current medical environment of antibiotic prophylaxis and antenatal steroid use, taking into account the changes in patient characteristics.

Interventions

  • MisoprostolDrug
  • OxytocinDrug

Arms2

  • Active comparator

    Misoprostol

    Those randomized to the prostaglandin arm will receive PGE1 (misoprostol) in a dose of 25mcg placed vaginally every 4 hours as per hospital protocol.

  • Active comparator

    Oxytocin Alone

    Those randomized to the oxytocin arm will receive infusion of oxytocin, which will then be titrated per hospital protocol or until adequate contractions.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Rate of Cesarean Section

    Time frame · within 48 hours

    Registry description

    Mode of delivery via cesarean section or vaginal delivery

Secondary outcomes(1)
  1. Maternal and Neonatal Infectious Morbidity

    Time frame · within 72 hours

    Registry description

    Maternal infection defined as fever \>100.4 on at least two occasions during labor, continued antibiotic treatment on or after PPD#1, histologic confirmation of chorioamnionitis. Dose of Oxytocin, Tachysystole, Estimated blood loss at delivery, maternal length of stay, Epidural use, Indication for cesarean delivery Neonatal infection defined as WBC \<5000 and absolute neutrophil count \<1000 or positive blood cultures and neonatal fever, NICU admission, Apgar score less than 7 at 5 minutes,

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeNumber· within 48 hours

Rate of Cesarean Section

GroupValue (participants)
Vaginal Misoprostol27
Oxytocin Alone26
Secondary and other outcome results(1)
Secondary outcomeCount of participants· within 72 hours

Maternal and Neonatal Infectious Morbidity

GroupValue (Participants)
Vaginal Misoprostol13
Oxytocin Alone15

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
MisoprostolThose randomized to the prostaglandin arm will receive PGE1 (misoprostol) in a dose of 25mcg placed vaginally every 4 hours as per hospital protocol. Misoprostol: Patients who are randomized to receive misoprostol will have 25mcg placed vaginally. Repeated dosing of misoprostol is based on clinical exam and clinical judgment of the provider.0 / 1170 / 1170 / 117
Oxytocin AloneThose randomized to the oxytocin arm will receive infusion of oxytocin, which will then be titrated per hospital protocol or until adequate contractions. Oxytocin: Patients who are randomized to receive oxytocin alone will receive intravenous administration of oxytocin as designated by the hospital protocol. Protocol begins with 2 milliunits of oxytocin that is then titrated over time. Titration is based on clinical exam and clinical judgment of the provider and is continued until there are adequate uterine contractions.0 / 1130 / 1130 / 113

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies8

Studies that cite this trial.

More studies

8 studies on this page

Indexing hint: Randomized controlled trial · 2011

Comparison of induction of labor with vaginal misoprostol plus oxytocin versus oxytocin alone in term primigravidae.

Balci et al. 2011The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricianscited by 5

PMID 21087166DOI 10.3109/14767058.2010.531798PUB-21087166

Full text at the publisher
Publisher page

Indexing hint: Meta-analysis (pooled) · 2006

Planned early birth versus expectant management (waiting) for prelabour rupture of membranes at term (37 weeks or more).

Dare et al. 2006The Cochrane database of systematic reviewscited by 48

PMID 16437525DOI 10.1002/14651858.cd005302.pub2PUB-16437525

Full text at the publisher
Publisher page

Indexing hint: Randomized controlled trial · 1999

Randomized, double-masked comparison of oxytocin dosage in induction and augmentation of labor.

Merrill et al. 1999Obstetrics and gynecologycited by 59

PMID 10472877DOI 10.1016/s0029-7844(99)00338-5PUB-10472877

Full text at the publisher
Publisher page

Indexing hint: Randomized controlled trial · 1998

Induction of labor with misoprostol for premature rupture of membranes beyond thirty-six weeks' gestation.

Wing et al. 1998American journal of obstetrics and gynecologycited by 44

PMID 9704771DOI 10.1016/s0002-9378(98)70256-xPUB-09704771

Full text at the publisher
Publisher page

Indexing hint: Randomized controlled trial · 1996

Induction of labor compared with expectant management for prelabor rupture of the membranes at term. TERMPROM Study Group.

Hannah et al. 1996The New England journal of medicinecited by 256

PMID 8598837DOI 10.1056/nejm199604183341601PUB-08598837

Rights unknown
Source link

Indexing hint: Randomized controlled trial · 1994

Intracervical prostaglandin E2 for induction of labor in patients with premature rupture of membranes and an unripe cervix.

Gonen et al. 1994American journal of perinatologycited by 9

PMID 7857439DOI 10.1055/s-2007-994615PUB-07857439

Full text at the publisher
Publisher page

Indexing hint: Randomized controlled trial · 1992

Role of prostaglandin in the management of prelabour rupture of the membranes at term.

Mahmood et al. 1992British journal of obstetrics and gynaecologycited by 21

PMID 1554660DOI 10.1111/j.1471-0528.1992.tb14466.xPUB-01554660

Full text at the publisher
Publisher page

Indexing hint: Randomized controlled trial · 1984

Management of premature rupture of membranes and unfavorable cervix in term pregnancy.

Duff et al. 1984Obstetrics and gynecologycited by 72

PMID 6717874PUB-06717874

Full text at the publisher

Other registry references

References listed at the registry that are not in PepBank. They link to PubMed.

  • ResultMercer BM. Preterm premature rupture of the membranes: current approaches to evaluation and management. Obstet Gynecol Clin North Am. 2005 Sep;32(3):411-28. doi: 10.1016/j.ogc.2005.03.003. PMID 16125041
  • ResultKunze M, Hart JE, Lynch AM, Gibbs RS. Intrapartum management of premature rupture of membranes: effect on cesarean delivery rate. Obstet Gynecol. 2011 Dec;118(6):1247-1254. doi: 10.1097/AOG.0b013e3182351b0c. PMID 22105253
  • ResultVrouenraets FP, Roumen FJ, Dehing CJ, van den Akker ES, Aarts MJ, Scheve EJ. Bishop score and risk of cesarean delivery after induction of labor in nulliparous women. Obstet Gynecol. 2005 Apr;105(4):690-7. doi: 10.1097/01.AOG.0000152338.76759.38. PMID 15802392
  • ResultKenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev. 2013 Dec 2;2013(12):CD001058. doi: 10.1002/14651858.CD001058.pub3. PMID 24297389

Eligibility

Who could join, as posted.

Sex
Female
Age
from 15 Years up to 50 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: 1. All pregnant women diagnosed with PROM without evidence of labor requiring induction 2. Gestational Age \> 34 weeks 3. Bishop score \< 6 4. Category I Fetal heart rate tracing Exclusion Criteria: 1. Contraindication to Induction of Labor 2. Multiple gestation 3. Fetal Anomalies 4. Previous C-Section 5. HIV Positive Patients

PepBank is a research reference. Talk to a doctor before you use any peptide.